News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
Friday, May 19, 2023AbbVie NYSE ABBV today announced that the US Food and Drug Administration FDA has approved RINVOQ upadacitinib for the treatment of adults with moderately to severely active Crohns disease who have had an inadequate response or intolerance to one or...
GenScript Expands Peptide and Oligonucleotide Production Facility in China
Friday, May 19, 2023GenScript Biotech Corporation the worlds leading provider of lifescience research tools and services has expanded its primary manufacturing facility for oligonucleotide and peptide production at Zhenjiang Jiangsu China The expansion builds on GenScri...
Revvity Announces New License Agreement for Next-Generation Base Editing Technology
Friday, May 19, 2023Revvity Inc NYSE RVTY today announced a new license agreement with AstraZeneca LSESTONasdaq AZN for the technology underlying its Pinpoint base editing system a nextgeneration modular gene editing platform with a strong safety profile
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction
Thursday, May 18, 2023Sania Therapeutics the Company focused on developing genetic medicines for neural circuit dysfunction launches today by unveiling its suite of proprietary patented platforms at the American Society of Gene Cell Therapy ASGCT conference
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Thursday, May 18, 2023Takeda TSE NYSETAK today announced that the US Food and Drug Administration FDA has accepted Takedas Biologics License Application BLA for TAK an enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura cTTP an A...
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
Thursday, May 18, 2023Antengene Corporation Limited Antengene SEHK HK a leading innovative commercialstage global biopharmaceutical company dedicated to discovering developing and commercializing firstinclass andor bestinclass therapeutics in hematology and oncology today...
Amneal Launches Third Biosimilar with FYLNETRA™ in the United States
Wednesday, May 17, 2023Amneal Pharmaceuticals Inc NYSE AMRX Amneal or the Company today announced the commercial launch of FYLNETRA pegfilgrastimpbbk a biosimilar referencing Neulastain a prefilled singledose syringe FYLNETRA is used to treat neutropenia low neutrophils wh...
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762
Wednesday, May 17, 2023Phio Pharmaceuticals Corp Nasdaq PHIO a clinical stage biotechnology company whose proprietary INTASYL RNAi platform technology is designed to make immune cells more effective in killing tumor cells today announced that the US Food and Drug Administr...
Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection
Wednesday, May 17, 2023Shorla Oncology Shorla a USIreland pharmaceutical company and EVERSANA a leading provider of commercialization services to the life science industry today announced the commercial launch of the companys oncology drug Nelarabine Injection for the trea...
Kimera® Labs Receives FDA Phase I/IIa IND Approval For Its MSC Exosomes Human Study
Wednesday, May 17, 2023Kimera Labs Inc the first and leading worldwide MSC exosome research lab and producer is pleased to announce the FDA IND Investigational New Drug approval of its exosomes in a Phase IIIa clinical trial The trial will assess the safety and efficacy of...
